製品名:tert-butyl (3S)-3-methylpiperazine-1-carboxylate

IUPAC Name:tert-butyl (3S)-3-methylpiperazine-1-carboxylate

CAS番号:147081-29-6
分子式:C10H20N2O2
純度:98%
カタログ番号:CM102431
分子量:200.28

包装単位 有効在庫 価格(USD) 数量
CM102431-100g in stock ƴǟ
CM102431-500g in stock ŽřŁ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:147081-29-6
分子式:C10H20N2O2
融点:-
SMILESコード:C[C@H]1CN(CCN1)C(=O)OC(C)(C)C
密度:
カタログ番号:CM102431
分子量:200.28
沸点:
MDL番号:MFCD02683204
保管方法:Keep in dark place, inert atmosphere, store at 2-8°C.

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

Column Infos

Fenebrutinib
Roche’s investigational drug, Fenebrutinib has shown brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis (MS) from the recent release of new data from Phase II FENopta study. Fenebrutinib is a potent and highly selective Bruton’s tyrosine kinase (BTK) inhibitor, and currently the only reversible inhibitor being tested in Phase III MS trials. BTK inhibitor is involved in key pathological features of MS, including B-cell development and activation.
Sotorasib
Dec. 26, 2023, Amgen announced that the U.S. FDA has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS (sotorasib).
LUMAKRAS (sotorasib) is an oral, first-in-class therapy indicawithted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) following at least one previous systemic therapy.
Sotorasib is the first approved targeted therapy for patients with tumors with any KRAS mutation, which accounts for approximately 25% of mutations in NSCLC. The U.S. FDA granted the application for sotorasib orphan drug, fast track, priority review, and breakthrough therapy designations.

Related Products